Table 1 Clinical characteristics of the 60 patients treated with IDH inhibitors.

From: Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Characteristics Median IQR
WBC 1.8 1.1–3.1
 ANC 0.2 0.0–0.6
HGB 9.4 8.6–10.4
PLT 47 24–76
BM blast, % 41 20–63
PB blast, % 6 0–28
Age 72 60–77
  No. %
Diagnosis
  AML 55 92
  MDS 4 7
  CMML 1 2
Karyotype
  Normal 24 40
  Complex 13 22
  Trisomy 8 10 17
  Deletion 5 3 5
  11q23 3 5
  Other 13 22
Sex
  Female 25 42
  Male 35 58
Treatment
  Ivosidenib 22 37
  Enasidenib 38 63
Best response
  CR 12 20
  CRp 7 12
  MLFS 7 12
  HI with platelet and neutrophil response 1 2
  PR 3 5
  SD 28 47
  PD 1 2
  Not assessed 1 2
IDH-differentiation syndrome
  Yes 11 18
  No 49 82
  1. Source data are provided as a Source data file.
  2. IQR interquartile range, WBC white blood cells, ANC absolute neutrophil count, HGB hemoglobin, PLT platelets, BM bone marrow, PB peripheral blood, No. number, AML acute myeloid leukemia, MDS myelodysplastic syndrome, CMML chronic myelomonocytic leukemia, CR complete remission, CRp CR with incomplete platelet recovery, MLFS morphological leukemia-free state, HI hematological improvement, PR partial remission, SD stable disease, PD progressive disease.